Effect of diltiazem and thromboxane A2 synthetase inhibitor (OKY-046) on vessels following experimental subarachnoid hemorrhage.
In order to examine the functional changes in the vascular smooth muscle, the effects of a thromboxane A2 synthetase inhibitor (OKY-046) and a calcium channel blocker (diltiazem) on vessels following subarachnoid hemorrhage, and the contractile activity of cerebral vessels with various vasoactive agents, were investigated by studying isometric tension recordings in rings of cat basilar artery. The maximum contractile activities of the vessels in response to noradrenalin and adrenaline during the course of subarachnoid hemorrhage were significantly less than those in the control group. On the other hand, the maximum contractile activity of the vessels in response to prostaglandin F2 alpha on the seventh day following subarachnoid hemorrhage was significantly augmented compared with that in the control group. A significant decline in the relaxation of responsiveness to diltiazem during the course of subarachnoid hemorrhage was observed compared with that of diltiazem in the control group. This responsiveness to vasoactive agents was not influenced by the application of OKY-046. The present study reveals functional changes in vascular smooth muscle exposed to subarachnoid hemorrhage in response to vasoactive agents and a calcium entry blocker. Thromboxane A2 may not be a significantly influential factor in the present results. It is suggested that cerebral vasospasm may well be related to functional changes of the arterial wall, which appear to be associated with derangement of the mechanisms of smooth muscle constriction and dilatation based on organic changes.
Yoshida
K
K
Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan.
Nakamura
S
S
Umezawa
T
T
Nakano
M
M
Tsubokawa
T
T
D000818:Animals; D001488:Basilar Artery / Q000503:physiopathology; D002415:Cats; D004110:Diltiazem / Q000494:pharmacology*; D015237:Dinoprost / Q000494:pharmacology; D004195:Disease Models, Animal; D004837:Epinephrine / Q000494:pharmacology; D008689:Methacrylates / Q000494:pharmacology*; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology*; D009638:Norepinephrine / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013345:Subarachnoid Hemorrhage / Q000503:physiopathology*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D008689:Methacrylates; D012701:Serotonin; D015237:Dinoprost; D013930:Thromboxane-A Synthase; D004110:Diltiazem; C034364:ozagrel; D009638:Norepinephrine; D004837:Epinephrine